PrognoScan: a new database for meta-analysis of the prognostic value of genes.

Mizuno H, Kitada K, Nakai K, Sarai A. · 2009

Read PrognoScan: a new database for meta-analysis of the prognostic value of genes. by Mizuno H, Kitada K, Nakai K, Sarai A. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2689870.txt.

Introduction

Mizuno, Kitada, Nakai, and Sarai built in 2009 PrognoScan, a public database for testing whether a gene's activity predicts cancer patients' survival. Public archives held many cancer gene datasets with patient outcomes attached, gold for finding tumor markers, but scattered and hard to analyze without specialist tools. PrognoScan gathers them into one platform.

A user picks a gene, and the system splits patients by its activity level at the cut point that best separates their survival curves, then checks the link's strength. Rather than fixing one arbitrary split, it searches for the most informative one, while guarding against the false patterns such searching can invent. Repeating the test across many datasets acts as a meta-analysis: a gene that predicts outcomes again and again earns trust. The database is free online, aimed at speeding the hunt for markers and drug targets.

Catalog record

CREATORMizuno H, Kitada K, Nakai K, Sarai A.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2689870

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

PrognoScan: a new database for meta-analysis of the prognostic value of genes By Hideaki Mizuno, Kunio Kitada, Kenta Nakai, Akinori Sarai Published in: BMC Medical Genomics DOI: 10.1186/1755-8794-2-18 ABSTRACT Abstract Background In cancer research, the association between a gene and clinical outcome suggests the underlying etiology of the disease and consequently can motivate further studies. The recent availability of published cancer microarray datasets with clinical annotation provides the opportunity for linking gene expression to prognosis. However, the data are not easy to access and analyze without an effective analysis platform. Description To take advantage of public resources in full, a database named "PrognoScan" has been developed. This is 1) a large collection of publicly available cancer microarray datasets with clinical annotation, as well as 2) a tool for assessing the biological relationship between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis that finds the optimal cutpoint in continuous gene expression measurement without prior biological knowledge or assumption and, as a result, enables systematic meta-analysis of multiple datasets. Conclusion PrognoScan provides a powerful platform for evaluating potential tumor markers and therapeutic targets and would accelerate cancer research. The database is publicly accessible at http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html. BACKGROUND A number of genes are recognized as being potentially relevant to cancers. One way to evaluate such genes is to assess their relationship to prognosis. At present, many cancer microarray datasets with clinical annotation have become available in the public domain and provide vast opportunities to link gene expression to prognosis. However, the data are not easy to access and analyze without an effective analysis platform. Standard survival analysis consists of two steps: 1) grouping patients and 2) comparing the risk difference of the groups. When conducting survival analysis based on continuous measurement such as gene expression, determination of the appropriate cutpoints for groupings remains a critical and difficult task. Thus, although two pioneer databases, ITTACA [1] and REMBRANDT http://rembrandt.nci.nih.gov, have provided survival analysis functionality with user defined cutpoints for several focused cancer microarray datasets, researchers without prior biological knowledge or assumptions for the gene may end up using an arbitrary threshold (e.g. median, tertile, quartile) that does not necessarily reflect the biology of the gene or may laboriously test a number of possible cutpoints. The minimum P-value approach is a comprehensive method to find the optimal risk separation cutpoint in continuous measurements and have shown the utility in the analyses of tumor size [2], cell cycle phase estimation measurement [3], and gene copy number [4]. In addition, it is intuitive for oncologists, and thus, a systematic application of this approach to gene expression from microarray seems logical. Recent studies have reported expression thresholds at which the gene becomes a contributor to the development of the cancer such as Bub1 for tumorigenesis [5], HOXB4 for cellular transformation [6], and MYC for tumor maintenance [7], and provided a rationale for the application to gene expression. Thus, we developed "PrognoScan", a database featuring a large collection of publicly available cancer microarray datasets with clinical annotation and a tool for assessing the relationship between gene expression and prognosis using the minimum P-value approach. This database enables systematic meta-analysis of the prognostic value of a gene in multiple datasets and consequently will accelerate cancer research. CONSTRUCTION AND CONTENT Data collection Cancer microarray datasets with clinical annotation were intensively collected from the public domain including Gene Expression Omnibus (GEO) [8], ArrayExpress [9] and individual laboratory web sites, under the following criteria: 1) includes patient information on survival event and time, 2) contains large enough sample sizes to enable survival analysis, 3) is derived from a 'whole genome' platform and has no values missing so quantile normalization will function properly and 4) is derived from a platform for which probe annotation for a public identifier (e.g. gene symbol, GenBank accession number, UniGene ID) is available. As of February 2009, the collection included more than 40 datasets of various cancer types spanning a wide range of cancers including bladder, blood, breast, brain, esophagus, head and neck, kidney, lung, and ovarian (Table 1) [10-35], far more comprehensive than both ITTACA, which focuses on bladder cancer, breast cancer and uveal melanoma, and REMBRANDT, which specializes in brain cancers. Because some samples were used more than once by more than one study, the origin of the samples was checked. Sample duplications within a dataset were dealt with by leaving one representative arbitrary. Sample overlaps among datasets were accepted, because the study design designated by each contributor may be of value. The collected microarray datasets were standardized by using quantile normalization. Probe annotations were retrieved from GEO and ArrayExpress. Each probe was mapped to an Entrez Gene ID by querying the accompanied public identifier in UniGene database. The information in the dataset was manually curated and includes 1) study design-cohort, cancer type, subtype, endpoint, therapy history and pathological parameters-and 2) experimental procedure-sample preparation, storage, array type and signal processing method. To assess prognostic value of genes in various contexts, available endpoints such as overall survival (OS), recurrence free survival (RFS), event free survival (EFS), and distant-metastasis free survival (DMFS) were adopted as much as possible. All tables were relationally linked and stored in the MySQL server. [Table: Dataset content from PrognoScan] Data analysis Survival analysis in PrognoScan employs the minimum P-value approach [2] to find the cutpoint in continuous gene expression measurement for grouping patients. First, patients are ordered by expression value of a given gene. Next, patients are divided into two (high and low) expression groups at all potential cutpoint, and the risk differences of the two groups are estimated by log-rank test. Then, optimal cutpoint that gives the most pronounced P-value (Pmin) is selected. This exploratory approach, however, is known to cause inflation of a type I error because it conducts multiple correlated testing [36-38]. Thus, P-value correction is conducted to control the error rate using the following formula [39]. where z is the (1 - Pmin /2)-quantile of the standard normal distribution, φ denotes the standard normal density function, and [ε, 1 - ε] denote the range of the quantile considered to be cutpoints. PrognoScan uses ε = 0.1 to avoid small groupings from cutpoints of < 0.1 or > 0.9 quantile. For any given gene, this cutpoint determination and prognostic value assessment can be applied to all possible combinations of dataset, endpoint and probe. For convenience, we term each combination as "test". Note that, because probe design for each gene differs, the number of possible tests varies according to the gene. For statistical analysis and visualization, R packages http://www.r-project.org are used. UTILITY The top page of PrognoScan is quite simple and the user need only input gene identifier(s) (Fig. 1A). To show the features of the database and its utility, we give three meta-analysis examples. The first example is MKI67, a well known tumor proliferation marker. The prognostic value of MKI67 protein expression has been reported for many types of malignant tumor including brain, breast, and lung cancer and a few exceptions for certain tumors such as non-Hodgkin's lymphoma [40]. When given the gene, PrognoScan displays a summary in table format of tests for the gene with columns for dataset, cancer type, subtype, endpoint, cohort,

Read the complete text